This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Advanced Solid Tumors
and you are
between 18 and 90
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The main purpose of this study is to test the safety of three study drugs, bevacizumab (Avastin™), Everolimus (Afinitor™) and LBH589 (Panobinostat) when they are given together. It is hoped this study drug combination might lead to a greater decrease the in size of the cancer and/or slow down how fast the cancer is growing compared to when these drugs are given alone. Subjects will be enrolled at Duke University Medical Center (DUMC).

Provided treatments

  • Drug: Bevacizumab, Everolimus and LBH589

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01055795. The sponsor of the trial is Herbert Hurwitz and it is looking for 14 volunteers for the current phase.
Official trial title:
Phase I Study of the Combination of Bevacizumab, Everolimus and LBH589 (BEL) for the Treatment of Advanced Solid Tumors